Oxandrolone Compared With Megestrol in Preventing Weight Loss in Patients Receiving Chemotherapy for Cancer



Status:Completed
Conditions:Cancer, Obesity Weight Loss
Therapuetic Areas:Endocrinology, Oncology
Healthy:No
Age Range:18 - Any
Updated:8/15/2018
Start Date:March 2004
End Date:August 2007

Use our guide to learn which trials are right for you!

A Phase III Randomized Study Comparing The Effects Of Oxandrolone (Oxandrin) And Megestrol Acetate (Megace) On Lean Body Mass, Weight, Body Fat, And Quality Of Life In Patients With Solid Tumors And Weight Loss Receiving Chemotherapy

RATIONALE: Oxandrolone and megestrol may help prevent weight loss and improve quality of life
in patients with cancer. It is not yet known whether oxandrolone is more effective than
megestrol in preventing weight loss and improving quality of life in patients who are
receiving chemotherapy for solid tumors.

PURPOSE: This randomized phase III trial is studying oxandrolone to see how well it works
compared to megestrol in preventing weight loss and improving quality of life in patients who
are receiving chemotherapy for solid tumors.

OBJECTIVES:

- Compare the lean body mass and weight of patients with solid tumors and weight loss who
are receiving chemotherapy when treated with oxandrolone vs megestrol.

- Compare the health-related quality of life of patients treated with these drugs.

OUTLINE: This is a randomized, multicenter study. Patients are stratified according to
disease stage (I-III vs IV), concurrent radiotherapy (yes vs no), and gender. Patients are
randomized to 1 of 2 treatment arms.

- Arm I: Patients receive oral oxandrolone twice daily.

- Arm II: Patients receive oral megestrol once daily. In both arms, treatment continues
for 12 weeks in the absence of excessive weight loss or gain or unacceptable toxicity.

Quality of life, weight, and body composition are assessed at baseline, at 1, 2, and 3 months
during study therapy, and then at 1 month after study completion.

Patients are followed at 1 month.

PROJECTED ACCRUAL: A total of 62-155 patients (31-77 per treatment arm) will be accrued for
this study within 2 years.

INCLUSION CRITERIA:

- Age >18 years with no pre-existing or uncontrolled medical or psychological illness
that would impair a patient's ability to provide informed consent or to complete
protocol therapy or quality of life questionnaires.

- A minimum of one month planned chemotherapy remaining at the time Oxandrin or
Megestrol acetate is begun. Oral chemotherapy medications, biologicals, and monoclonal
antibodies are included in eligibility criteria.

- Histologically confirmed solid tumor (see exceptions in ineligibility list)

- Female patients with a history of breast cancer, gynecologic cancer, and hormonally
responsive germ cell tumors must be disease free > 5 years to be eligible for this
study

- Patients with non-melanoma skin cancers and carcinoma in situ of the cervix are
eligible.

- History of weight loss of:

1. > 5% total body weight during the previous 6 months OR

2. > 3% in previous month OR

3. Progressive weight loss on 2 consecutive visits despite attempts at dietary,
behavioral, or pharmacologic intervention.

- ECOG Performance Status of 0-2

- Life expectancy > 6 months

- Serum creatinine < 2.5mg/dl, SGOT and SGPT < 2 times upper limit of normal, total
bilirubin < 2.5 mg/dl

- Patients must be able to swallow 1 tablet twice a day or 20 cc of liquid each day

- Patients must be able to meet their nutritional requirements via the oral route with
food and/or oral supplements or via enteral tube feedings. However, Oxandrin pills
must be administered orally.

- Patients who are taking warfarin for maintenance of central venous catheter patency
are eligible for this trial if their INR < 1.2. Because of the interaction between
warfarin and Oxandrin, the maintenance dose of warfarin in eligible patients should be
halved to keep the INR at 1-1.2. For example, if a patient is taking 1 mg of warfarin
at study entry, it is recommended that the dose be decreased to 0.5 mg per day, their
dose should be decreased to every other day, every third day, etc. to keep the INR at
< 1.2. The INR must be checked weekly until stable at < 1.2.

- Patients can be receiving concurrent RT.

EXCLUSION CRITERIA:

- Ongoing or planned treatment with corticosteroid medications, estrogens, progestins
(including Megestrol acetate) or any other steroid hormone during the study period.
Patients who receive intermittent corticosteroids as part of a pre-chemotherapy
antiemetic regimen are eligible for this study. Patients treated with Oxandrin or
Megestrol acetate < 3 months before study entry are not eligible. Patients taking
dronabinol or any other appetite stimulant must be off medication for a minimum of 3
days prior to start of study medication.

- Patients who have had the following are ineligible:

- Prostate cancer

- Male breast cancer

- Female breast, gynecologic, or hormonally responsive germ cell tumors in the last 5
years

- Primary or metastatic malignant brain tumors that have not been stable or demonstrate
progressive disease in the last 6 months.

- Leukemia, lymphoma, myeloma or other hematologic malignancies

- Men > 40 years of age should have a prostate-specific antigen (PSA) level checked if
not monitored in the past year. Those patients with PSA > 4 ng/mL will be excluded
from participation in the study. If required, the PSA should be done within 2 weeks
prior to registration.

- Patients with hypercalcemia, nephrosis or the nephrotic phase of nephritis or
uncontrolled hypertension, congestive heart failure, pulmonary edema, unstable angina
or Cushing's syndrome.

- Patients with recent (within 6 months) active thromboembolic disease or recent
myocardial infarction (within 3 months of study entry).

- Systemic anticoagulation: Patients currently on oral anticoagulants (warfarin) are not
eligible unless they are taking low doses of warfarin for catheter patency. If a
patient develops thromboembolic disease while on treatment, they may remain on study.
It is recommended that they receive a standard loading dose of coumadin on day 1.
because of the interaction between Oxandrin and Coumadin (Oxandrin elevates the INR),
patients will subsequently require a much lower dose of Coumadin. The effect of these
combined medications should develop within 24 to 48 hours. The recommended Coumadin
dose should be decreased to 20% of what is normally required for sufficient
anticoagulation. (Example: If patient would normally receive 5 mg every day, they
should only receive 1 mg every day.) PT/INR results should be monitored frequently
with dosage adjustment as needed.

- Significant ascites, pleural effusions or edema which may inhibit oral food intake or
invalidate weight determinations.

- Diabetic medications are allowed, however patients taking sulfonyureas are ineligible.
Below is a list of commonly used sulfonyureas (Note: This is a helpful guide, not a
complete list.):

Glimepiride (Amaryl®), glyburide (DiaBeta®), chlorpropamide (Diabinese®),
glipizide(Glucatrol®), combined glyburide and metformin (Glucovance®) and orinase
(Tolbutamide®).

There is no contraindication for concomitant use of insulin and oxandrolone (Oxandrin®) if
required by the patient. Any patient on insulin or other oral hypoglycemics should
self-monitor to prevent hypo & hyperglycemia.

- Patients who are pregnant or nursing.

- Patients with history of priapism (persistant erections) and sickle cell anemia.

- Patients with a BMI(Body Mass Index) ≥ 35
We found this trial at
20
sites
Asheville, North Carolina 28801
?
mi
from
Asheville, NC
Click here to add this to my saved trials
200 Hawthorne Lane
Charlotte, North Carolina 28233
704-384-4000
Presbyterian Cancer Center at Presbyterian Hospital At Novant Health Presbyterian Medical Center, we are welcoming...
?
mi
from
Charlotte, NC
Click here to add this to my saved trials
600 Moye Boulevard
Greenville, North Carolina 27834
?
mi
from
Greenville, NC
Click here to add this to my saved trials
33 Villa Road, Suite 400
Greenville, South Carolina 29615
(864) 404-2045
CCOP - Greenville Cancer care in the last decade has made many advances. Most of...
?
mi
from
Greenville, SC
Click here to add this to my saved trials
4300 Alton Road
Miami Beach, Florida 33140
(305) 674-2625
CCOP - Mount Sinai Medical Center The Mount Sinai Community Clinical Oncology Program (MSCCOP) is...
?
mi
from
Miami Beach, FL
Click here to add this to my saved trials
1 Medical Center Blvd
Winston-Salem, North Carolina 27103
(336) 716-2011
Wake Forest University Comprehensive Cancer Center Our newly expanded Comprehensive Cancer Center is the region’s...
?
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
?
mi
from
Baton Rouge, LA
Click here to add this to my saved trials
?
mi
from
Burlington, NC
Click here to add this to my saved trials
1335 Dublin Road, Suite 124A
Columbus, Ohio 43215
(614) 488-2118
CCOP - Columbus As one of the original 20 CCOPs, the Columbus Community Clinical Oncology...
?
mi
from
Columbus, OH
Click here to add this to my saved trials
142 S Main St
Danville, Virginia 24541
(434) 799-2100
Danville Regional Medical Center For more than 120 years, Danville Regional Medical Center has been...
?
mi
from
Danville, VA
Click here to add this to my saved trials
Goldsboro, North Carolina 27534
?
mi
from
Goldsboro, NC
Click here to add this to my saved trials
Goldsboro, North Carolina 27534
?
mi
from
Goldsboro, NC
Click here to add this to my saved trials
?
mi
from
Greensboro, NC
Click here to add this to my saved trials
800 N Justice St
Hendersonville, North Carolina 28791
(828) 696-1000
Pardee Memorial Hospital Pardee Hospital is a not-for-profit community hospital founded in 1953 and is...
?
mi
from
Hendersonville, NC
Click here to add this to my saved trials
High Point, North Carolina 27261
?
mi
from
High Point, NC
Click here to add this to my saved trials
Louisville, Kentucky 40202
?
mi
from
Louisville, KY
Click here to add this to my saved trials
?
mi
from
Martinsville, VA
Click here to add this to my saved trials
533 Bolivar Street, Room 420
New Orleans, Louisiana 70112
(504) 568-3435
MBCCOP - LSU Health Sciences Center Established in 1990, the Stanley S. Scott Cancer Center...
?
mi
from
New Orleans, LA
Click here to add this to my saved trials
?
mi
from
Newark, DE
Click here to add this to my saved trials
Spartanburg, South Carolina 29303
?
mi
from
Spartanburg, SC
Click here to add this to my saved trials